SARS-CoV-2 Virus Neutralization, BioAssay(TM) (Spike Protein/ACE2 Ligand Binding Assay) (Research Use Only)

Product Overview

• Article Name: SARS-CoV-2 Virus Neutralization, BioAssay(TM) (Spike Protein/ACE2 Ligand Binding Assay) (Research Use Only)
• Biozol Catalog Number: USB-544523
• Supplier Catalog Number: 544523
• Alternative Catalog Number: USB-544523-96
• Manufacturer: US Biological
• Category: Kits/Assays
• Alternative Names: sars-cov-2

Product Description

The SARS-CoV-2 Virus Neutralization BioAssay(TM) (Spike Protein/ACE2 Ligand Binding Assay) is a qualitative competitive ELISA for the determination of inhibition of SARS-CoV-2 spike protein binding to ACE2. Background: The emergence of the COVID-19 pandemic resulting from the spread of the SARS-CoV-2 virus has ignited a massive global research effort for development of COVID-19 vaccines, therapeutics, and diagnostic tests for viral infections and antibody responses. These time-critical efforts have also put into focus the need for better approaches for immune response analysis in both the human population exposed to the wild virus and in vaccine studies. In addition to population monitoring and vaccine studies, ligand binding assays may be of use in library screens to identify monoclonal antibodies, peptides, and small molecules, that may block infection or lower the infection rate of SARS-CoV-2 virus. The World Health Organization has recently cautioned that positive results from antibody tests (IgM and IgG antibody tests) do not equal protective immunity owing to the fact that most antibodies in an immune response are not neutralizing and in fact may enhance infection. Current available antibody tests are for detection of binding antibodies, and do not differentiate neutralizing antibodies from total antibodies. The presence of neutralizing antibodies may or may not correlate with protection in SARS-CoV-2 serum, although neutralizing antibody levels is a good indicator of protective immunity in many other viral models. Sample Type: This kit is compatible with EDTA-plasma, heparin-plasma and serum samples. Test Principle (Research Use Only): This SARS-CoV-2 spike protein ligand binding assay allows rapid quantification of COVID-19 neutralizing antibodies in serum and plasma by measuring reduction in the binding of viral spike protein with its receptor ACE2. This assay allows rapid analysis of convalescent plasma, antibody-based therapeutics, vaccine leads, and immune response to the virus. This serological platform was designed as a tool to begin understanding the correlation between neutralizing antibody level and protective immunity in recovered SARS-CoV-2. Features: Rapid: 1.5 hours total time Versatile: No cells or virus used, therefore suitable for USL1 lab Open Platform: 96 well plate reader Precision: Intra-assay CV: <10% Inter-assay CV: <10% Kit Components: Coated assay plate, 96Tests 1X assay buffer, 1x50ml 10X wash buffer, 1x50ml 100X detection reagent, 1x30ul TMB, 1x12ml TMB stop solution, 1x12ml Note: Do not mix or substitute reagents with those from other lots. Ready-To-Use Calibrator Samples (Human Serum Samples With Calibrated Blocking Activity): Calibrator 1 (125ul), 0% inhibition Calibrator 2 (125ul), 20% inhibition Calibrator 3 (125ul), 40% inhibition Calibrator 4 (125ul), 60% inhibition Calibrator 5 (125ul), 80% inhibition Calibrator 6 (125ul), 100% inhibition Storage and Stability: Store kit components at -20C unless specified otherwise. Do not use past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening. Samples can be stored at or below -20C for up to 1 year after receipt.